Back to Results
First PageMeta Content
Chemistry / Incontinence / Overactive bladder / Solifenacin / Urinary incontinence / Astellas Pharma / Urge incontinence / Urinary retention / Frequent urination / Medicine / Urology / Muscarinic antagonists


August 29, 2011 Astellas Pharma Inc.: Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder, in U.S. and Europe Tokyo, August 29, [removed]Astellas Pharma Inc. (Tokyo:4503, “As
Add to Reading List

Document Date: 2011-08-26 02:56:51

Open Document

File Size: 52,34 KB

Share Result on Facebook

City

Tokyo / /

Company

Astellas Pharma Inc. / /

Continent

Europe / /

Country

Taiwan / Japan / United States / Korea / China / India / /

Event

FDA Phase / /

/

IndustryTerm

treatment of overactive bladder with symptoms / /

MedicalCondition

intestinal obstruction / Overactive Bladder / urinary retention / narrow-angle glaucoma / urge incontinence / urinary incontinence / urge urinary incontinence / uncontrolled narrow-angle glaucoma / Angioedema / hypersensitivity / fecal impaction / constipation / angioneurotic edema / cases angioedema / /

Organization

European Medicines Agency / U.S. Food and Drug Administration / /

/

Product

OAB medication / Vesicare / ketoconazole / China / YM178 / Betanis® tablet / /

URL

http /

SocialTag